Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. by Jarius, S, Frederikson, J, Waters, P, Paul, F, Akman-Demir, G, Marignier, R, Franciotta, D, Ruprecht, K, Kuenz, B, Rommer, P, Kristoferitsch, W, Wildemann, B, Vincent, A

Treatment of Neuromyelitis Optica: Review and Recommendations. by Kimbrough, D, Fujihara, K, Jacob, A, Lana-Peixoto, M, Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, de Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG, Wingerchuk, D

Treatment of neuromyelitis optica: Review and recommendations by Kimbrough, D, Fujihara, K, Jacob, A, Lana-Peixoto, M, Isabel Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, De Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG, Wingerchuk, D, Guthy Jackson Charitable Foundation Clinical Consortium and Biorepository

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial by Cree, BAC, Bennett, JL, Kim, HJ, Weinshenker, BG, Pittock, SJ, Wingerchuk, DM, Fujihara, K, Paul, F, Cutter, GR, Marignier, R, Green, AJ, Aktas, O, Hartung, H-P, Lublin, FD, Drappa, J, Barron, G, Madani, S, Ratchford, JN, She, D, Cimbora, D, Katz, E

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. by Collongues, N, Marignier, R, Jacob, A, Leite, M, Siva, A, Paul, F, Zephir, H, Akman-Demir, G, Elsone, L, Jarius, S, Papeix, C, Mutch, K, Saip, S, Wildemann, B, Kitley, J, Karabudak, R, Aktas, O, Kuscu, D, Altintas, A, Palace, J, Confavreux, C, De Seze, J

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. by Kaneko, K, Sato, D, Nakashima, I, Nishiyama, S, Tanaka, S, Marignier, R, Hyun, J, Oliveira, L, Reindl, M, Seifert-Held, T, Sepulveda, M, Siritho, S, Waters, P, Kurosawa, K, Akaishi, T, Kuroda, H, Misu, T, Prayoonwiwat, N, Berger, T, Saiz, A, Kim, H, Nomura, K, Callegaro, D, Fujihara, K, Aoki, M

Characterization of NMO and NMOSD Patients with a Late Onset by Collongues, N, Marignier, R, Jacob, A, Siva, A, Paul, F, Zephir, H, Leite, M, Akman-Demir, G, Elsone, L, Jarius, S, Papeix, C, Mutch, K, Saip, S, Wildemann, B, Kitley, J, Karabudak, R, Aktas, O, Kuscu, D, Altintas, A, Palace, J, Confavreux, C, De Seze, J

Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease by Hacohen, Y, Wong, Y, Lechner, C, Jurynczyk, M, Wright, S, Konuskan, B, Kalser, J, Poulat, A, Maurey, H, Ganelin-Cohen, E, Wassmer, E, Hemingway, C, Forsyth, R, Hennes, E, Leite, M, Ciccarelli, O, Anlar, B, Hintzen, R, Marignier, R, Palace, J, Baumann, M, Rostásy, K, Neuteboom, R, Deiva, K, Lim, M

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes by Juryńczyk, M, Weinshenker, B, Akman-Demir, G, Asgari, N, Barnes, D, Boggild, M, Chaudhuri, A, D’hooghe, M, Evangelou, N, Geraldes, R, Illes, Z, Jacob, A, Kim, H, Kleiter, I, Levy, M, Marignier, R, McGuigan, C, Murray, K, Nakashima, I, Pandit, L, Paul, F, Pittock, S, Selmaj, K, de Sèze, J, Siva, A, Tanasescu, R, Vukusic, S, Wingerchuk, D, Wren, D, Leite, I, Palace, J